 Kazia Therapeutics Limited ASX: KZA; NASDAQ: KZIA, an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. This data is the subject of a poster presentation at the annual meeting of the Society for Neuro-Oncology SNO, held in Phoenix, AZ from 20 - 24 November 2019. 